Elderly individuals have started to withdraw from Novovax’s coronavirus disease 2019 (COVID-19) vaccine trial; California reports possible allergic reactions to the Moderna COVID-19 vaccine; LGBTQ individuals increasingly report being refused health care treatment.
Hoping to instead get an approved vaccine from Pfizer or Moderna, individuals 65 years and older have initiated requests to drop out of Novovax’s coronavirus disease 2019 (COVID-19) vaccine trial, reports The Washington Post. Following expanded vaccine eligibility rules, they are asking to be unblinded in order to know if they got the placebo or the experimental vaccine. The trial began enrollment on December 28, 2020, with a goal of having 30,000 enrollees—it currently has just 9000—of whom a fourth are 65 years and older because of their higher risk of serious disease. Novovax previously encountered a trial roadblock because it did not have its own manufacturing facility, so it was kicked out of its contracted manufacturer facility to make room for Johnson & Johnson.
As reported by the California Department of Public Health, batch 041L20A of Moderna’s COVID-19 vaccine may be responsible for several allergic reactions coming out of 1 vaccination center in San Diego, according to the company. Over 1.2 million doses were produced in this batch, with 330,000 sent to 287 providers in California, 93% of which have not been distributed. Following a manufacturing review for this lot, along with its shipping and storage records, Moderna has said that all necessary criteria were met. Similar occurrences of allergic reactions from this batch or other batches have not been reported.
Up to one-third of transgender individuals in North Carolina have reported that their health care providers have refused to treat them or have inflicted verbal or physical abuse, reports Kaiser Health News. Advocates in the state are pushing for nondiscrimination legislation following the December 1 expiration of a ban prohibiting enactment of such laws. Areas that could be affected include employment, housing, and health care—particularly the loss of health insurance from a firing based on sexual identity. A chief source of concern is the outgoing Trump administration’s removal of Affordable Care Act provisions that blocked sexual orientation– and gender identity–based discrimination practices by social service providers.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More